Skip to content
Angion Biomedica Corp

Angion Biomedica Corp

ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS

  • about
    • executive management
    • scientific advisory board
    • board of directors
  • our science
    • HGF/c-Met Pathway
    • Acute Kidney Injury
    • Acute Lung Injury
    • CNS Injury
  • pipeline
    • ANG-3777
    • ANG-3070
    • ROCK2 Inhibitor
    • CYP11B2 Inhibitor
  • Investors
    • stock information
      • stock quote & chart
    • press releases
    • events & presentations
    • financial information
      • SEC filings
    • governance
    • investor resources
      • investor contact
      • investor FAQs
      • email alerts
  • publications
  • careers
  • contact

Member Category: Executive Management

Greg Curhan

Greg Curhan

Jennifer Rhodes

Jennifer Rhodes

John F. Neylan, MD

John F. Neylan, MD

Itzhak Goldberg, MD, FACR

Itzhak Goldberg, MD, FACR

Jay Venkatesan, MD, MBA

Jay Venkatesan, MD, MBA

CATEGORIES

  • RSL-HGF
  • RSL-ALI
  • Fibrosis
  • ROCKi
  • angion publications
  • RSL-AKI
  • events

CORPORATE ADDRESS

51 Charles Lindbergh Boulevard
Uniondale, NY 11553

Navigation

  • home
  • about
  • our science
  • pipeline
  • investors
  • publications
  • careers
  • contact

© 2021 Angion. All Rights Reserved.
Legal and Privacy Policy

NEW YORK | SAN FRANCISCO | BOSTON